GLG News by Ophthalmologists who Treat Macular Degeneration (US)

This Phase III Clinical Trial clearly shows that focal grid laser is better than steroids in the management of Diabetic Macular Edema (DME).  This reaffirms laser as the current gold standard in the management of DME and casts doubts on numerous treatment modalities in the pipeline that use steroids...

The Visian ICL (Implantable Collamer Lens) is an exquisitely precise technology for the correction of high degrees of nearsightedness -- much higher than the reach of laser refractive surgery such as LASIK and PRK.  Given the price of the ICL and the intraocular surgey required for its...

"He who pays the fiddler calls the tune."  Here's an example of the fiddler pro-actively asking the guy in the room with the deepest pocket what he'd like to hear.  If it's not something in the current repertoire, the fiddler seems willing to learn.  However, by the time he's got...

I and many other ophthalmologists around the country use Avastin intravitreally for wet macular degeneration in doses far smaller than those used for systemic cancer.  Although it is an "off-label" use of the drug, the cost for using Avastin is 1/6oth of Lucentis, a very similar...

Many patients who have irregular astigmatism will find a disposable silicone hydrogel lens to provide good vision with less irritation of the cornea due to protein build up in the lens.  This could be a big help to those who may not be LASIK candidates or who are awaiting future Custom LASIK surgery...

This article warns against "taking testing out of the hands of companies" and warns against the idea that a drug is receiving a Phase 3 trial without early phase testing.  The CATT trial certainly marks a huge change in drug development but what the pharma industry is not appreciating...

The FDA report and scrutiny of LASIK complaints reveals what consientious LASIK surgeons have known for years:  Not everyone who walks through your doors is a good lasik candidate and you should not laser everyone.  About 1 out of 4 patients that consider lasik are actually good candidates...

The media reporting on the FDA hearings on LASIK has generally highlighted unhappy patients' stories and the comments of FDA officials and panel members.  However, The Washington Post's Lauran Neergard has written an insightful article that foresees an important future trend in refractive surgery....

A new model of the increasing popular Ex-Press Shunt is quite effective in an early study.  Its is quite safe and effective; and simpler substitute for trabeculectomy.  It could be the first line  in the surgical management of glaucoma.

Alcon (ACL) reported positive interim results for their injectable medication for glaucoma.  A single injection of anecortave acetate  resulted in control of IOP at the three month follow up.  This could be a promising medication for IOP control in glaucoma.